Top Tech Companies (2,065)
Don't see your company?
Create a company profile
SillaJen Biotherapeutics, Inc. is located in San Francisco, one of the largest and most innovative biotech clusters in the world. Sillajen Biotherapeutics focuses on the research, development and manufacturing of oncolytic viruses to treat cancer; we are responsible for Clinical Operations, Regulatory Affairs, Research and Development, Manufacturing, Alliance Management and Accounting for clinical trials. SillaJen, Inc. is a South Korean based biotechnology company headquartered in Busan South Korea, with satellite offices in Seoul, South Korea and San Francisco, CA. The company is focused on the development and commercialization of oncolytic immunotherapy products using the SOLVETM platform, including its lead product Pexa-Vec, which is currently in Phase 3 trials for the treatment of advanced primary liver cancer. Additional information about SillaJen is available at www.sillajen.com.
WinSanTor Inc. is a clinical-stage biotechnology company focused on the discovery and development of treatments for peripheral neuropathies.
Official LinkedIn page for Esperion. Esperion is The Lipid Management Company. Our goal is lipid management for everybody, that’s why we work hard to make our medicines accessible. We discover, develop and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by the status quo. Our entrepreneurial team of industry leaders is inclusive, passionate and resourceful. For more information, please visit esperion.com and follow us on Twitter at www.twitter.com/EsperionInc. Community guidelines: https://bit.ly/3vLCGdO
Opko Health engages in the discovery and development of novel and proprietary technologies for pharmaceuticals and diagnostics.
Incisive Surgical, Inc. is a privately-held medical device company established to develop proprietary mechanical surgical solutions for
Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies. The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment. Immune-Onc has a promising pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) of myeloid checkpoints. The company has strategic research collaborations with The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center, and has invested in proprietary models, assays and tools to interrogate the biology and translate this cutting-edge research into the development of novel therapies. Immune-Onc’s lead program IO-202, a first-in-class antibody targeting LILRB4 (also known as ILT3), is being developed to treat acute myeloid leukemia (AML) and other cancers. IO-202 is the first T-cell activator for AML. In September 2020, Immune-Onc initiated a Phase I trial evaluating IO-202 in blood cancers, AML and chronic myelomonocytic leukemia (CMML). The company plans to evaluate IO-202 in solid tumors and in other forms of blood cancer in the near future. In addition to IO-202, Immune-Onc’s pipeline includes IO-108, an antibody targeting LILRB2 (also known as ILT4) in the IND-enabling stage of development. Additional preclinical candidates focused on myeloid checkpoints include an anti-LAIR1 antibody and multiple undisclosed programs for solid tumors and hematologic malignancies. For more information, please visit www.immune-onc.com.
Praxis Biosresearch is a privately-held biopharmaceutical company.
DiaKine Therapeutics is a development stage company commercializing novel immune modulators for the treatment of diabetes.
Intezyne Technologies develops synthetic polymers for drug delivery and the treatment of cancer.
.jpg)
SDC delivers top-tier clinical trial services to pharmaceutical, biologic, and medical device/diagnostic companies since 2005. We are committed to providing experienced teams who will take ownership of your needs and are positively engaged in your projects. With strategic scientific consulting and clinical data services (biostatistics, data management/EDC, and IRT/IWRS) expertise at our core, our services are scalable via our diverse and complementary strategic partnerships to provide full service clinical trial solutions. Speak with us today to see why SDC is The Right Fit For You.®
ILiAD Biotechnologies is utilizing its B-Tech vector platform to develop next generation vaccines to eradicate infectious diseases and improve lives. Its lead candidate, BPZE1, which has completed Phase 2 clinical trials, is the most advanced next generation vaccine for the prevention of whooping cough, a serious illness caused by Bordetella pertussis.
ThinkCyte’s mission is to provide scientists and biomedical professionals with a transformational single-cell technology that accelerates biological discoveries and enable the development of novel treatments and diagnostics through the integration of advanced hardware, machine learning, and biotechnology.
Medisyn Technologies is a unique bioactive compound design and discovery company for novel pharmaceuticals, nutraceuticals and animal health products. Through its proprietary Forward Engineering™ technology platform, Medisyn makes bioactive compound discovery faster, more predictable and less expensive. Based on molecular topology, Medisyn’s platform enables the discovery and design of novel, diverse and unexpected compounds in new chemical classes that meet exact parameters for a specific therapeutic use. By compressing design and discovery time from years to months and optimizing lead candidates, Medisyn’s novel approach enables customers to reduce risk, improve probability of success and control costs associated with the traditional lead discovery process.
Allied BioScience is dedicated to developing innovative solutions with sound science, to create cleaner human environments.
ImpriMed provides cutting-edge personalized medicine easily accessible for pets with blood cancer diseases. ImpriMed’s key product, Chemo Response Prediction Service has been used by board-certified veterinary oncologists, helping over 2,000 dogs with lymphoma and leukemia. With ImpriMed’s services, veterinarians make their treatment decisions quickly and with confidence. This innovative approach to cancer care has been published in a scientific journal and presented at major conferences and is supported by over 150 veterinary oncologists at 80+ specialty hospitals in the US.
Nanospectra Biosciences develops particle-based therapies for the selective and precise thermal destruction of solid tumors.
Meditrina Pharmaceuticals, a clinical-stage pharmaceutical company, develops innovative therapies that treat women's reproductive disorders.
Endothelix, Inc. is a cardiovascular device company based in Houston, Texas and is focused on non-invasive vascular function measurement.
AKESOgen is a biomarker, genomics and pharmacogenomics contract research organization.
BioMicro Systems develops and markets biological research products based on its proprietary microfluidic and microarray technologies.
